| abstract |
A use of a benzoquinone compound for inhibiting the Wnt/β-catenin signaling pathway of melanoma cells, and a pharmaceutical composition or supplement prepared using the benzoquinone compound. The benzoquinone compound contains a structure represented by the compound (I): wherein R1 is a hydrogen group or [(C4H4)CH3]n, n is an integer of 1-5; and R2 is a hydrogen group or a methoxy group. |